Shah Capital intends to vote against Novavax's board nominees, executive compensation

Shah Capital will vote against the re-election of board nominees and Novavax's executive compensation package at the upcoming annual meeting, escalating activist pressure on the vaccine maker. This raises governance risk for management, could prompt a proxy contest or strategic changes, and is likely to increase near-term share volatility (potentially moving the stock low-single-digit percentages).

Analysis

Shah Capital will vote against the re-election of board nominees and Novavax's executive compensation package at the upcoming annual meeting, escalating activist pressure on the vaccine maker. This raises governance risk for management, could prompt a proxy contest or strategic changes, and is likely to increase near-term share volatility (potentially moving the stock low-single-digit percentages).